• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

制备 pH 依赖性乌洛托品控释微丸以提高其生物利用度。

Preparation of pH-dependent modified-release pellets of urapidil to improve its bioavailability.

机构信息

College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, PR China.

出版信息

Pharm Dev Technol. 2011 Jun;16(3):212-8. doi: 10.3109/10837451003592191. Epub 2010 Feb 15.

DOI:10.3109/10837451003592191
PMID:20151942
Abstract

OBJECTIVE

Modified-release pellets containing urapidil were developed and its in vivo bioavailability was investigated.

METHODS

Lactose and MCC were used as the main fillers to prepare drug-layer pellets by the powder layering method using centrifugal granulation, and coated in a fluidized bed coater. Pellets with different drug release characteristics were prepared with a methacrylic acid copolymer aqueous dispersion.

RESULTS

Using commercial German capsules as the reference (R), two coating formulations were selected for tests after optimization: pH-dependent pellets with a ratio of Eudragit(®) NE30D/L30D55 of 10:1, a 3% coating level (T(1)), and pH-independent pellets with a Eudragit(®) NE30D coating level (T(2)) of 3.5%. The bioavailability of the pellets (T(1), T(2), containing 30 mg urapidil) was determined in six healthy subjects after oral administration of a single dose, for a period of three weeks, in the form of a crossover design with a wash-out period of one week. The plasma concentrations of urapidil were determined by HPLC with UV detection. The C(max) (maximum concentration), T(max), and MRT of T(1) were 311.7 ng/mL, 5.3 h and 8.3 h, respectively. T(1) was bioequivalent to R, with a relative bioavailability 110.9%. The C(max) and T(max), of T(2) were 105.3 ng/mL and 13.3 h, respectively, and the relative bioavailability was 72.7%.

CONCLUSION

The pH-dependent urapidil pellets have a high bioavailability.

摘要

目的

研制含有乌拉地尔的控释微丸,并考察其体内生物利用度。

方法

以乳糖和 MCC 为主要填充剂,采用离心造粒的粉末包衣法,用流化床包衣机包衣,制备载药层微丸。用甲基丙烯酸共聚物水分散体制备具有不同释药特性的微丸。

结果

选用商品化的德国胶囊(R)作为参比制剂,经优化后选择两种包衣处方进行考察:Eudragit(R)NE30D/L30D55 比例为 10∶1,包衣增重 3%的 pH 依赖性微丸(T(1))和 Eudragit(R)NE30D 包衣增重 3.5%的 pH 不依赖性微丸(T(2))。以单剂量、三周期、一周洗脱期的交叉设计,在 6 名健康受试者中进行口服给药后微丸(T(1)、T(2)中分别含 30mg 乌拉地尔)的生物利用度试验。用 HPLC-UV 法测定乌拉地尔的血药浓度。T(1)的 C(max)(峰浓度)、T(max)和 MRT 分别为 311.7ng/ml、5.3h 和 8.3h。T(1)与 R 生物等效,相对生物利用度为 110.9%。T(2)的 C(max)和 T(max)分别为 105.3ng/ml 和 13.3h,相对生物利用度为 72.7%。

结论

pH 依赖性乌拉地尔微丸具有较高的生物利用度。

相似文献

1
Preparation of pH-dependent modified-release pellets of urapidil to improve its bioavailability.制备 pH 依赖性乌洛托品控释微丸以提高其生物利用度。
Pharm Dev Technol. 2011 Jun;16(3):212-8. doi: 10.3109/10837451003592191. Epub 2010 Feb 15.
2
Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets.盐酸二甲双胍缓释微丸的制备及体内外评价
Eur J Pharm Biopharm. 2006 Oct;64(2):185-92. doi: 10.1016/j.ejpb.2006.04.004. Epub 2006 May 10.
3
In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.通过挤出/滚圆法制备的肠溶包衣淀粉基微丸的体外和体内评价
Eur J Pharm Biopharm. 2008 Sep;70(1):302-12. doi: 10.1016/j.ejpb.2008.04.019. Epub 2008 Apr 29.
4
In vitro and in vivo evaluation of ofloxacin sustained release pellets.氧氟沙星缓释微丸的体外和体内评价
Int J Pharm. 2008 Aug 6;360(1-2):47-52. doi: 10.1016/j.ijpharm.2008.04.014. Epub 2008 Apr 16.
5
Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs.比格犬中缓释多索茶碱微丸的制备及生物利用度
Drug Dev Ind Pharm. 2008 Jul;34(7):676-82. doi: 10.1080/03639040701836552.
6
Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability.制备和体外-体内评价增强生物利用度的非胃驻留双嘧达莫(DIP)缓释微丸。
Int J Pharm. 2012 Jan 17;422(1-2):9-16. doi: 10.1016/j.ijpharm.2011.10.014. Epub 2011 Oct 6.
7
Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium.双涂层和基质型控释微丸制剂的制备及体内外评价。
Int J Pharm. 2011 Mar 15;406(1-2):84-90. doi: 10.1016/j.ijpharm.2010.12.043. Epub 2011 Jan 8.
8
Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.硫酸吗啡片和盐酸纳曲酮片经粉碎后与原研产品及纳曲酮溶液的相对口服生物利用度:一项在健康志愿者中进行的单次、随机、开放、三交叉试验。
Clin Ther. 2010 Jun;32(6):1149-64. doi: 10.1016/j.clinthera.2010.05.011.
9
[Studies on heart-protecting musk pH-dependent gradient-release pellets].[心脏保护麝香pH依赖型梯度释放微丸的研究]
Yao Xue Xue Bao. 2002 Oct;37(10):812-7.
10
A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.一项单剂量、三周期、六序列交叉研究,比较了空腹条件下健康墨西哥志愿者中镁丙戊酸盐溶液、混悬液和肠溶片剂的生物利用度。
Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.

引用本文的文献

1
Novel Esomeprazole Magnesium-Loaded Dual-Release Mini-Tablet Polycap: Formulation, Optimization, Characterization, and In Vivo Evaluation in Beagle Dogs.新型载埃索美拉唑镁双释放微型片多效胶囊:比格犬体内的处方、优化、表征及评价
Pharmaceutics. 2022 Jul 5;14(7):1411. doi: 10.3390/pharmaceutics14071411.